CyMedica Gets CE Mark for Muscle Atrophy Treatment

CyMedica Orthopedics has received the CE mark for its QB1 muscle activation system to treat patients in Europe suffering from quadriceps muscle atrophy.

The patented system is incorporated with a postoperative knee brace to activate and stimulate atrophied muscles with little pain.

Based in Scottsdale, Ariz., CyMedica is a privately held company that develops and commercializes devices that target muscle atrophy, which can occur following ACL and total knee replacement surgery.

The QB1 received 510(k) approval from the FDA in April and is being marketed to knee patients across the U.S. — John Bechtel